CoChat

Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer

Open access
Sinicrope, Frank A., Okamoto, Koichi, Kasi, Pashtoon M., Kawakami, Hisato · 2016 · Clinical Gastroenterology and Hepatology
Cited by 116

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

Colorectal cancer (CRC) is a disease in which pathogenesis is influenced by genetic and epigenetic events that occur with tumor initiation and progression. Precision oncology is becoming increasingly important in the management and therapy of CRC since large variation exists in individual patient prognosis and response to chemotherapy that is due to molecular heterogeneity. Certain biomarkers have been identified that can be utilized to predict clinical outcome beyond staging, and to inform treatment selection. Molecular testing is routinely performed in clinical practice for the selection of patients for targeted biologic agents or immunotherapy, and is advocated for prognostic stratification. Estimating prognosis can inform treatment decisions with avoidance of under or over treatment and also guide the intensity of patient follow-up. Classifiers of CRC have been developed that integrate genetic and/or epigenetic features which can provide prognostic and predictive information. The mutational status of KRAS and BRAFV600E combined with analysis of the DNA mismatch repair system with/without CIMP has been shown to identify colon cancer subtypes with distinct clinical features and prognoses. Gene expression profiling has also been used to subtype CRCs and can overcome the limitations of single/limited gene testing. A recent effort identified four consensus molecular subtypes of biological relevance that were associated with different patient outcomes. Efforts to validate and refine these subtypes to include additional genomic features are ongoing. In addition to the potential for molecular subtypes to predict therapeutic efficacy, they can inform the development of new agents in a subtype–specific manner to accelerate drug-discovery efforts. The focus of this article is to highlight molecular markers that can inform clinical decision-making in patients with CRC. Molecular profiling–based stratification

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cgh.2016.02.008

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 116

Metadata

Authors
Sinicrope, F. A., Okamoto, K., Kasi, P. M., & Kawakami, H.
Venue
Clinical Gastroenterology and Hepatology
Publisher
Elsevier BV
Published
2016-05
Volume
14
Issue
5
Pages
651-658
ISSN
1542-3565 (ISSN-L)
OpenAlex
W2268912183
Cited by
116
References
18
FWCI
9.74
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer. https://app.cochat.ai/papers/10.1016/j.cgh.2016.02.008
The paper
Sinicrope, F. A., Okamoto, K., Kasi, P. M., & Kawakami, H. (2016). Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2016.02.008

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.